Relay Therapeutics, Inc.
RLAY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $10 | $26 | $1 | $3 |
| % Growth | -60.8% | 1,749.8% | -54.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $10 | $26 | $1 | $3 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $319 | $330 | $246 | $173 |
| G&A Expenses | $77 | $75 | $66 | $57 |
| SG&A Expenses | $77 | $75 | $66 | $57 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$13 | -$6 | -$12 | $138 |
| Operating Expenses | $382 | $399 | $301 | $368 |
| Operating Income | -$372 | -$373 | -$299 | -$365 |
| % Margin | -3,722.1% | -1,460.1% | -21,670.9% | -12,040.2% |
| Other Income/Exp. Net | $35 | $31 | $9 | $1 |
| Pre-Tax Income | -$338 | -$342 | -$291 | -$364 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$338 | -$342 | -$291 | -$364 |
| % Margin | -3,374.7% | -1,338.7% | -21,036.1% | -12,012.9% |
| EPS | -2.36 | -2.79 | -2.59 | -3.82 |
| % Growth | 15.4% | -7.7% | 32.2% | – |
| EPS Diluted | -2.36 | -2.79 | -2.59 | -3.82 |
| Weighted Avg Shares Out | 143 | 123 | 112 | 95 |
| Weighted Avg Shares Out Dil | 143 | 123 | 112 | 95 |
| Supplemental Information | – | – | – | – |
| Interest Income | $35 | $31 | $9 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $5 | $5 | $4 | $4 |
| EBITDA | -$380 | -$374 | -$307 | -$223 |
| % Margin | -3,799.4% | -1,464.6% | -22,217.4% | -7,364.9% |